Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Communicating genetic risk of disease estimates does not impact individuals' health related behaviors, according to a review published March 15 in the…
From - Diagnostic Testing & Emerging Technologies
A new breast cancer staging system adds HER2 (ERBB2-positive disease) status to a list of factors used to assess prognosis in women who undergo neoadjuvant (pre-surgical) therapy for…